276 related articles for article (PubMed ID: 29053203)
1. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
[TBL] [Abstract][Full Text] [Related]
2. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
Wu T; Wong CKH; Tang EHM; Man KKC; Wong SKH; Au ICH; Tse ETY; Chan EWY; Grieve E; Wu O; Ng EKW; Wong ICK
Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
[TBL] [Abstract][Full Text] [Related]
3. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Angelidi AM; Kokkinos A; Sanoudou D; Connelly MA; Alexandrou A; Mingrone G; Mantzoros CS
Metabolism; 2023 Jan; 138():155346. PubMed ID: 36375643
[TBL] [Abstract][Full Text] [Related]
4. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
[TBL] [Abstract][Full Text] [Related]
5. Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
Chen JH; Tang WH; Lee CH
J Med Case Rep; 2014 Sep; 8():304. PubMed ID: 25213589
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB; Renström F; Aczél S; Folie P; Biraima-Steinemann M; Beuschlein F; Bilz S
Obes Surg; 2023 Apr; 33(4):1017-1025. PubMed ID: 36765019
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.
Zhu H; Zhou L; Wang Q; Cai Q; Yang F; Jin H; Chen Y; Song Y; Zhang C
Ann Rheum Dis; 2023 Sep; 82(9):1218-1226. PubMed ID: 37258065
[TBL] [Abstract][Full Text] [Related]
9. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
Morissette A; Mulvihill EE
J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
[TBL] [Abstract][Full Text] [Related]
10. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
Diabetes Obes Metab; 2024 Jun; ():. PubMed ID: 38934217
[TBL] [Abstract][Full Text] [Related]
11. Weight loss during medical weight management does not predict weight loss after bariatric surgery: a retrospective cohort study.
Abbott S; Lawson J; Singhal R; Parretti HM; Tahrani AA
Surg Obes Relat Dis; 2020 Nov; 16(11):1723-1730. PubMed ID: 32771426
[TBL] [Abstract][Full Text] [Related]
12. Effect of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy on fasting gastrointestinal and pancreatic peptide hormones: A prospective nonrandomized trial.
Yang J; Gao Z; Williams DB; Wang C; Lee S; Zhou X; Qiu P
Surg Obes Relat Dis; 2018 Oct; 14(10):1521-1529. PubMed ID: 30449509
[TBL] [Abstract][Full Text] [Related]
13. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
Jones AG; McDonald TJ; Shields BM; Hill AV; Hyde CJ; Knight BA; Hattersley AT;
Diabetes Care; 2016 Feb; 39(2):250-7. PubMed ID: 26242184
[TBL] [Abstract][Full Text] [Related]
14. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.
Liu FP; Dong JJ; Yang Q; Xue XZ; Ren ZF; Gan YZ; Liao L
J Diabetes; 2015 May; 7(3):322-8. PubMed ID: 25047138
[TBL] [Abstract][Full Text] [Related]
16. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.
Kittah E; Camilleri M; Jensen MD; Vella A
Metab Syndr Relat Disord; 2020 Nov; 18(9):406-412. PubMed ID: 32833560
[No Abstract] [Full Text] [Related]
18. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
[TBL] [Abstract][Full Text] [Related]
19. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
Kobori T; Onishi Y; Yoshida Y; Tahara T; Kikuchi T; Kubota T; Iwamoto M; Sawada T; Kobayashi R; Fujiwara H; Kasuga M
J Diabetes Investig; 2023 Jun; 14(6):767-773. PubMed ID: 36919944
[TBL] [Abstract][Full Text] [Related]
20. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
